{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:12:54Z","timestamp":1771467174199,"version":"3.50.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01ES005775"],"award-info":[{"award-number":["R01ES005775"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA197574"],"award-info":[{"award-number":["R35CA197574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM126211-04"],"award-info":[{"award-number":["R01GM126211-04"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acquired resistance presents a major challenge for targeted therapies, with initially responsive tumors eventually reverting underlying vulnerabilities. Our group recently reported that cancers harboring isocitrate dehydrogenase 1\/2 (IDH1\/2) mutations have defective recruitment of homology-directed repair (HDR) factors to sites of DNA damage and consequent sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi), a vulnerability that is being tested in clinical trials. To probe potential mechanisms by which resistance to PARPi might arise in this setting, we modeled PARPi resistance in IDH-mutant tumors via serial transplantation of patient-derived xenografts in mice treated with PARPi. An analysis of candidate DNA repair factors in these resistant tumor populations identified downregulation of two end protection factors that are negative regulators of HDR, 53BP1, and REV7. Knockout of these factors by CRISPR\u2013Cas9 in IDH1-mutant cancer cells conferred robust resistance to PARPi and restored HDR capacity. To overcome this resistance, we found that treatment with the receptor tyrosine kinase inhibitor, cediranib, previously reported to suppress expression of downstream HDR factors, resensitizes 53BP1 and REV7-knockout cells to PARPi treatment. Our findings identify key pathways driving PARPi resistance in IDH1-mutant cancers and highlight potential therapeutic strategies to overcome this resistance.<\/jats:p>","DOI":"10.1093\/narcan\/zcaf047","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:34:21Z","timestamp":1761568461000},"source":"Crossref","is-referenced-by-count":1,"title":["PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4672-3493","authenticated-orcid":false,"given":"Daniel Andr\u00e9s","family":"Col\u00f3n-R\u00edos","sequence":"first","affiliation":[{"name":"Department of Genetics, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Department of Therapeutic Radiology, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1354-1124","authenticated-orcid":false,"given":"Jonathan","family":"Dow","sequence":"additional","affiliation":[{"name":"Department of Genetics, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Department of Therapeutic Radiology, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-7806","authenticated-orcid":false,"given":"Adam","family":"Krysztofiak","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8252-4288","authenticated-orcid":false,"given":"Yanfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-9892","authenticated-orcid":false,"given":"Faye\u00a0A","family":"Rogers","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-5560","authenticated-orcid":false,"given":"Peter M","family":"Glazer","sequence":"additional","affiliation":[{"name":"Department of Genetics, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]},{"name":"Department of Therapeutic Radiology, Yale School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2026020905314476500_B1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026020905314476500_B2","doi-asserted-by":"publisher","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026020905314476500_B3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski","year":"2020","journal-title":"Nature"},{"key":"2026020905314476500_B4","doi-asserted-by":"publisher","first-page":"eaaz3221","DOI":"10.1126\/sciadv.aaz3221","article-title":"Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas","volume":"6","author":"Wang","year":"2020","journal-title":"Sci Adv"},{"key":"2026020905314476500_B5","doi-asserted-by":"publisher","first-page":"9169","DOI":"10.1073\/pnas.1403565111","article-title":"DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin","volume":"111","author":"Ayrapetov","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020905314476500_B6","doi-asserted-by":"publisher","first-page":"e1601898","DOI":"10.1126\/sciadv.1601898","article-title":"CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair","volume":"3","author":"Hilmi","year":"2017","journal-title":"Sci Adv"},{"key":"2026020905314476500_B7","doi-asserted-by":"publisher","first-page":"10912","DOI":"10.1073\/pnas.1704076114","article-title":"CTCF prevents genomic instability by promoting homologous recombination-directed DNA double-strand break repair","volume":"114","author":"Lang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020905314476500_B8","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/s41467-025-56781-2","article-title":"D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming","volume":"16","author":"Lang","year":"2025","journal-title":"Nat Commun"},{"key":"2026020905314476500_B9","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.molcel.2023.05.026","article-title":"Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination","volume":"83","author":"Schvartzman","year":"2023","journal-title":"Mol Cell"},{"key":"2026020905314476500_B10","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1158\/0008-5472.CAN-23-2015","article-title":"Heterochromatin-dependent replication stress: a lesson from IDH1\/2 Mutants","volume":"83","author":"Zou","year":"2023","journal-title":"Cancer Res"},{"key":"2026020905314476500_B11","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"2026020905314476500_B12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"The Lancet"},{"key":"2026020905314476500_B13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026020905314476500_B14","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.3390\/cancers15143642","article-title":"Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches","volume":"15","author":"Dilmac","year":"2023","journal-title":"Cancers"},{"key":"2026020905314476500_B15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026020905314476500_B16","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1002\/1878-0261.13224","article-title":"Resistance to DNA repair inhibitors in cancer","volume":"16","author":"Baxter","year":"2022","journal-title":"Mol Oncol"},{"key":"2026020905314476500_B17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2026020905314476500_B18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","article-title":"Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells","volume":"20","author":"Dev","year":"2018","journal-title":"Nat Cell Biol"},{"key":"2026020905314476500_B19","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1038\/s41467-018-06407-7","article-title":"An OB-fold complex controls the repair pathways for DNA double-strand breaks","volume":"9","author":"Gao","year":"2018","journal-title":"Nat Commun"},{"key":"2026020905314476500_B20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","article-title":"DNA repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity","volume":"173","author":"Gupta","year":"2018","journal-title":"Cell"},{"key":"2026020905314476500_B21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/jmcb\/mjq055","article-title":"BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability","volume":"3","author":"Aly","year":"2011","journal-title":"J Mol Cell Biol"},{"key":"2026020905314476500_B22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nsmb.1831","article-title":"53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers","volume":"17","author":"Bouwman","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"2026020905314476500_B23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"2026020905314476500_B24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov"},{"key":"2026020905314476500_B25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 counteracts DNA double-strand break resection and affects PARP inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"key":"2026020905314476500_B26","doi-asserted-by":"publisher","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"2026020905314476500_B27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Ray\u00a0Chaudhuri","year":"2016","journal-title":"Nature"},{"key":"2026020905314476500_B28","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1158\/0008-5472.CAN-20-2912","article-title":"Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells","volume":"81","author":"F\u00e4rkkil\u00e4","year":"2021","journal-title":"Cancer Res"},{"key":"2026020905314476500_B29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1158\/2767-9764.CRC-22-0436","article-title":"Multicenter Phase II Trial of the PARP inhibitor olaparib in recurrent IDH1- and IDH2-mutant glioma","volume":"3","author":"Fanucci","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026020905314476500_B30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.molcel.2013.01.001","article-title":"A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice","volume":"49","author":"Escribano-D\u00edaz","year":"2013","journal-title":"Mol Cell"},{"key":"2026020905314476500_B31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.tcb.2021.05.009","article-title":"REV7 directs DNA repair pathway choice","volume":"31","author":"Clairmont","year":"2021","journal-title":"Trends Cell Biol"},{"key":"2026020905314476500_B32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026020905314476500_B33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat Methods"},{"key":"2026020905314476500_B34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"2026020905314476500_B35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1667\/RR14746.1","article-title":"The focinator v2-0 - graphical interface, four channels, colocalization analysis and cell phase identification","volume":"188","author":"Oeck","year":"2017","journal-title":"Radiat Res"},{"key":"2026020905314476500_B36","doi-asserted-by":"publisher","first-page":"e0240280","DOI":"10.1371\/journal.pone.0240280","article-title":"QuickFigures: a toolkit and ImageJ PlugIn to quickly transform microscope images into scientific figures","volume":"16","author":"Mazo","year":"2021","journal-title":"PLoS One"},{"key":"2026020905314476500_B37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"2026020905314476500_B38","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov"},{"key":"2026020905314476500_B39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","article-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","volume":"35","author":"Harvey-Jones","year":"2024","journal-title":"Ann Oncol"},{"key":"2026020905314476500_B40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature14216","article-title":"MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5\u2032 end resection","volume":"521","author":"Boersma","year":"2015","journal-title":"Nature"},{"key":"2026020905314476500_B41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-018-0362-1","article-title":"53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ","volume":"560","author":"Ghezraoui","year":"2018","journal-title":"Nature"},{"key":"2026020905314476500_B42","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.molcel.2022.01.025","article-title":"RIF1 acts in DNA repair through phosphopeptide recognition of 53BP1","volume":"82","author":"Setiaputra","year":"2022","journal-title":"Mol Cell"},{"key":"2026020905314476500_B43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"2026020905314476500_B44","doi-asserted-by":"publisher","first-page":"1516165","DOI":"10.3389\/fonc.2024.1516165","article-title":"REV7: a small but mighty regulator of genome maintenance and cancer development","volume":"14","author":"Maggs","year":"2024","journal-title":"Front Oncol"},{"key":"2026020905314476500_B45","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/nar\/gkt255","article-title":"Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells","volume":"41","author":"Bindra","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2026020905314476500_B46","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1541-7786.MCR-21-0456","article-title":"Vulnerability of IDH1-mutant cancers to histone deacetylase inhibition via orthogonal suppression of DNA repair","volume":"19","author":"Dow","year":"2021","journal-title":"Mol Cancer Res"},{"key":"2026020905314476500_B47","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1158\/0008-5472.CAN-16-2773","article-title":"Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res"},{"key":"2026020905314476500_B48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.dnarep.2014.04.008","article-title":"DNA-PK phosphorylation of RPA32 Ser4\/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe","volume":"21","author":"Ashley","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"2026020905314476500_B49","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res"},{"key":"2026020905314476500_B50","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026020905314476500_B51","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.21.02947","article-title":"Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: the results From National Cancer Institute 9984","volume":"41","author":"Kim","year":"2023","journal-title":"JCO"},{"key":"2026020905314476500_B52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/oncolo\/oyae163","article-title":"PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma","volume":"29","author":"Mohan","year":"2024","journal-title":"Oncologist"},{"key":"2026020905314476500_B53","doi-asserted-by":"publisher","first-page":"PO.20.00439","DOI":"10.1200\/PO.20.00439","article-title":"Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precision Oncol"}],"container-title":["NAR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/7\/4\/zcaf047\/65730178\/zcaf047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/7\/4\/zcaf047\/65730178\/zcaf047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T10:31:56Z","timestamp":1770633116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/narcancer\/article\/doi\/10.1093\/narcan\/zcaf047\/8364040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/narcan\/zcaf047","relation":{},"ISSN":["2632-8674"],"issn-type":[{"value":"2632-8674","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,7]]},"article-number":"zcaf047"}}